Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-κB activation

European Journal of Pharmacology

Volumn 448, Issue 1, 2002, Pages 19-26

  Hirano, Yoshiko ^a   Hirano, Fuminori ^c   Fujii, Hiroshi ^c   Makino, Isao ^c  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c NONE

Author keywords

Bile acid; Chenodeoxycholic acid; Fibrate; NF B (Nuclear factor B); PPAR (peroxisome proliferator activated receptor); RANTES

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CHENODEOXYCHOLIC ACID; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RANTES; BILE ACID; DNA; FIBRIC ACID DERIVATIVE; LUCIFERASE; MESSENGER RNA; PROTEIN;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METABOLISM; CONTROLLED STUDY; DNA BINDING; ENZYME ASSAY; GENETIC TRANSCRIPTION; HEPATOMA CELL; HUMAN CELL; LIVER CELL; PLASMID; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPORTER GENE; T LYMPHOCYTE;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHENODEOXYCHOLIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NF-KAPPA B; PROCETOFEN; RANTES; TUMOR CELLS, CULTURED; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0037067356     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01902-7     Document Type: Article

References (49)

1. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: Effect of ursodeoxycholic acid treatment
2. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: Increase in activated T and natural killer cells and recruitment of primed memory T cells
3. Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: Effects on bile formation and liver plasma membranes
4. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse
5. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
6. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
7. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration
8. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1
9. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators
10. Peroxisome proliferator-activated receptors in inflammation control
11. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
12. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma
13. Identification of a nuclear receptor that is activated by farnesol metabolites
14. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes
15. Functional interference of Sp1 and NF-κB through the same DNA binding site
16. Alternative splicing variants of IκBβ establish differential NF-κB signal responsiveness in human cells
17. Bile acids regulate RANTES gene expression through its cognate NF-κB binding sites
18. The peroxisome proliferator-activated receptor α (PPARα) regulates bile acid biosynthesis
19. Activation of a member of the nuclear hormone receptor superfamily by peroxisome proliferators
20. Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis
21. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid
22. Primary biliary cirrhosis
23. Pruritus associated with cholestasis. A review of pathogenesis and management
24. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
25. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis
26. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid
27. CD4+ T cell subsets defined by isoforms of CD45 in primary biliary cirrhosis
28. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
29. Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry
30. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report
31. Identification of a nuclear receptor for bile acids
32. Chemokine levels in human liver homogenates: Associations between GROα and histopathological evidence of alcoholic hepatitis
33. Thrombin stimulates cell proliferation in human fibroblast-like synoviocytes in nuclear factor-κB activation and protein kinase C mediated pathway
34. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: A preliminary study
35. Genomic organization and transcriptional regulation of the RANTES chemokine gene
36. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study
37. Bile acids: Natural ligands for an orphan nuclear receptor
38. The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7α-hydroxylase gene
39. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression
40. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group
41. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
42. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
43. Primary biliary cirrhosis: Clarifying the issues
44. Homozygous disruption of the murine mdr2 P glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
45. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis
46. 3 receptors
47. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR
48. Chemokines and T lymphocytes: More than an attraction
49. Primary biliary cirrhosis: Identification of two major M2 mitochondrial autoantigens